Professor Cass Byrnes discusses the treatment of cystic fibrosis patients with a CFTR modulator, and the evidence for the use of Trikafta

     Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is funded for people aged 6 years and above with cystic fibrosis (CF), subject to eligibility criteria. 

    Professor Cass Byrnes MBChB, FRACP, MD (Auckland), GCCE (New South Wales) is in the Paediatric Department of the University of Auckland and a Paediatric Respiratory Specialist at Starship Children's Health and Kidz First Hospital.

    NATIONAL HEART FAILURE NURSE MEETING 2022

    This is a series of video podcasts from the Inaugural National Heart Failure Nurse Meeting held in September 2022. The aims of the meeting were to create a platform to share best heart failure practice leveraging experience from senior nurses and clinicians and provide a forum for heart failure nurse networking.

    The advisory committee and chairs for this meeting were Lia Sinclair – HF Nurse Practitioner, Te Whatu Ora Palmerston North, and Paul Peacock - Clinical Nurse Specialist Heart Function, Te Whatu Ora, Nelson.

    This meeting was fully supported by Novartis NZ.

    Respiratory Watch: Work-up of severe asthma and choosing biologic therapies

    Dr Angela Moran

    Cardiology Watch: The Right Tests

     Professor Alexander Sasse

    Infectious Diseases Watch - The era of oral treatment courses in infectious diseases

    Mohammed Issa

    Haematology Watch - Monoclonal gammopathy of undetermined significance

     Dr Henry Chan

    Diabetes Management during Ramadan

    Presentation by:

    Dr Marwan Obaid, Sydney Endocrinologist and Clinical Lecturer at the University of New South Wales.

     

    In this podcast Dr Obaid gives an overview of the importance of Ramadan to Muslims and provides a practical guide on how to manage people with diabetes who wish to participate in Ramadan, which requires Muslims to abstain from food and drink from dawn to dusk for 30 days.
     

    Extended Prevention of Recurrent VTE

     Speaker: Dr Gordon Royle

    In this recording of a live webcast event held in August 2020, Dr Royle addressed an audience of GPs and nurse practitioners on extended prevention of recurrent venous thromboembolism in primary care with a focus on the recommendations in the THANZ 2019 VTE Guidelines.

    Gordon Royle is a graduate of Otago Medical School. After moving to Auckland he undertook a Masters in Molecular Biology, and went on to train in Haematology. For the last 19 years he has been working as a Haematologist and researcher at Middlemore Hospital, and is a senior lecturer at Auckland University's School of Medicine. A particular interest is Coagulation Haematology. His clinical research experience includes the role of PI in several new oral anticoagulant trials. Prior research experience includes seven years' molecular biology in the USA including two years at The Salk Institute.

    Immuno-Oncology Treatment for Colorectal Cancer

     Speaker Dr Dragan Damianovich.

    In this recording of a live webcast event held in July 2020,  Dr Damianovich addressed an audience of health professionals on developments in immuno-oncology in colorectal cancer. Dragan also presented updates from the recent virtual ASCO20 Conference.

    Dr Dragan Damianovich, MD (Zagreb) FRACP, has been a consultant Medical Oncologist at Auckland Hospital since 2006 and at Auckland Oncology since 2008. He is also the expert contributor to Colorectal Oncology Research Review. Dragan is also a member of the Australian Gastrointestinal Trials Group (AGITG), the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC).

     

    GORD – How to Optimise Management

     Presented by Gastroenterologist Alasdair Patrick

    Why are we weighting? Let’s start treating obesity

     Associate Professor Rinki Murphy

    Immuno-Oncology Treatment for Urothelial and Renal Cancer

     Speaker Alvin Tan, hosted by Steve Holliday

    In this recording of a live webcast event held in May 2020,  Dr Alvin Tan addressed an audience of NZ healthcare professionals on immuno-oncology in urothelial and renal cancer using case studies to demonstrate recent advances in this fascinating and fast-developing field.

    Alvin is a consultant medical oncologist specialising in genito-urinary cancers at Waikato Hospital and Braemar Hospital in Hamilton.
     

    An Overview of Immunotherapy Treatment options for Urothelial Carcinoma

    Dr Alvin Tan, Medical Oncologist, discusses immunotherapy treatments in the metastatic urothelial setting in NZ.

    Alvin is a consultant medical oncologist specialising in genito-urinary cancers at Waikato Hospital and Braemar Hospital in Hamilton.

    Insulin initiation, titration and escalation: A practical guide for busy clinicians in primary care

     Webinar - October 2019

    Presentation by:
    Carl Peters
    Endocrinologist, North Shore Hospital

    In this webinar, Dr Carl Peters provided clinicians with a practical guide to the use of insulin in patients with type 2 diabetes mellitus.

    Simplifying COPD Treatment – Associate Professor Rob Young
    Simplifying COPD Treatment

    GPCME, South
    Saturday August 10, 2019

    Presentation by:
    Associate Professor Robert Young
    Consultant Physician, Auckland Hospital

    In this Breakfast Symposium, Associate Professor Rob Young discusses the diagnosis of COPD and simplifying treatment in the New Zealand context. He also covers the benefits of dual bronchodilation, the place of inhaled corticosteroids and non-pharmacological treatment.

    ALK Mutated Lung Cancer: A Rare Subtype of Non-Small Cell Lung Cancer

    Dr Gareth Rivalland, Medical Oncologist, discusses ALK mutated lung cancer. He describes its characteristics, diagnosis and staging, and various treatment options.

     

    Gareth is a Medical Oncologist specialising in thoracic and skin cancers at Auckland City Hospital and Harbour Cancer Centre in Auckland.

    The Future of Immuno-Oncology

     Dr Robert Weinkove, Consultant Haematologist at Wellington Blood and Cancer Centre and Clinical Director at Malaghan Institute of Medical Research discusses the future of immuno-oncology. He outlines new treatment modalities and new combinations of immuno-oncology agents with conventional treatments.
     

    Asthma & Respiratory Foundation NZ Adult Asthma Guidelines: A Quick Reference Guide

     Presentation by:
    Professor Richard Beasley
    Physician at Wellington Regional Hospital, Director of the Medical Research Institute of New Zealand, and Professor of Medicine at Victoria University of Wellington. Adjunct Professor at the University of Otago and Visiting Professor, University of Southampton, United Kingdom.

    In this video podcast Professor Richard Beasley provides an outline of the NZ Adult Asthma Guidelines published in November 2016. The purpose of the Asthma Foundation of New Zealand Quick Reference Guide is to provide simple, practical, evidence-based recommendations for the diagnosis, assessment and management of asthma in adults in a quick reference format. Professor Beasley also focuses on the changes to the guidelines since they were last update in 2002.

    Toxicity of immune checkpoint inhibitors: Immune related side effects

     Dr Rosalie Stephens is a medical oncologist at Auckland Hospital with a special interest in treating melanoma and is a Trustee on the board of Melanoma NZ. In this video podcast Dr Stephens describes some of the side effects produced by the immune checkpoint inhibitor class of treatments.
     

    Breakfast Session - Shared Care of the IBD Patient

     GPCME 2018 - Rotorua
    Sunday  June 10, 2018

    Presentations by:
    Drs Rick Stein and Ali Jafer (Consultant Gastroenterologists)
    Phoebe Wu and Jacqui Fletcher (IBD Nurses)

    In this Breakfast Session held at GPCME 2018, Dr Rick Stein discussed the growing burden of IBD in NZ.
     
    Dr Ali Jafer and Phoebe Wu also presented on the value of and models for shared care for the IBD patient, and Jacqui Fletcher gave tips for primary care clinicians on the best approaches to managing IBD patients.
     
    The video production for this presentation was funded by Emerge Health.

    IBD in Primary Care – Practical Management Tips

     GPCME 2018 - Rotorua
    Saturday June 9, 2018

    Presentation by:
    Dr David Rowbotham
    Consultant Gastroenterologist, Department of Gastroenterology and Hepatology, Auckland Hospital

    In this workshop held at GPCME 2018, Dr David Rowbotham presented tips for primary care clinicians on the best approaches to managing IBD patients in everyday practice.  He also discussed some novel therapies, stopping treatment and the IBD clinical trials taking place at the Auckland District Health Board.
     
    The video production for this presentation was funded by Emerge Health.

    The importance of using tools beyond lifestyle in managing obesity

    Goodfellow Symposium
    Sunday 25 March 2018

    Presentation by:

    Professor John Dixon, Head of clinical obesity research at the Baker Heart and Diabetes Institute in Melbourne, Australia.

    In this Breakfast Symposium, Professor John Dixon focused on the importance of tools such as pharmacotherapy, meal replacements and bariatric surgery, as lifestyle enablers, in the management of obesity, a disease he notes should be approached in the same manner as other chronic illnesses.

    Immunotherapy for advanced melanoma: clinical outcomes

     Dr Rosalie Stephens is a medical oncologist at Auckland Hospital with a special interest in treating melanoma and is a Trustee on the board of Melanoma NZ. In this video podcast Dr Stephens describes the clinical outcomes achieved with immunotherapy for advanced melanoma.

    Advances in Immuno-Oncology

     Dr Robert Weinkove, Consultant Haematologist at Wellington Blood and Cancer Centre and Clinical Director at Malaghan Institute of Medical Research introduces the topic of immuno-oncology.  He discusses current and emerging classes of cancer immunotherapies and gives an overview of their mechanisms of action, current place in treatment and recognition of adverse effects in primary care.
     

    Treating CLL with novel therapies

     Professor Peter Hillmen